JP2025501865A - 抗ｌｉｇｈｔ抗体で喘息を治療する方法 - Google Patents

抗ｌｉｇｈｔ抗体で喘息を治療する方法 Download PDF

Info

Publication number
JP2025501865A
JP2025501865A JP2024532504A JP2024532504A JP2025501865A JP 2025501865 A JP2025501865 A JP 2025501865A JP 2024532504 A JP2024532504 A JP 2024532504A JP 2024532504 A JP2024532504 A JP 2024532504A JP 2025501865 A JP2025501865 A JP 2025501865A
Authority
JP
Japan
Prior art keywords
light
subject
light antibody
antibody
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501865A5 (enExample
Inventor
ギャリー エー． ニール，
エイチ． ジェフリー ウィルキンス，
シェリダン ジェイ． キャリントン，
Original Assignee
アヴァロ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴァロ セラピューティクス， インコーポレイテッド filed Critical アヴァロ セラピューティクス， インコーポレイテッド
Publication of JP2025501865A publication Critical patent/JP2025501865A/ja
Publication of JP2025501865A5 publication Critical patent/JP2025501865A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024532504A 2022-01-05 2023-01-04 抗ｌｉｇｈｔ抗体で喘息を治療する方法 Pending JP2025501865A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296786P 2022-01-05 2022-01-05
US63/296,786 2022-01-05
US202263396308P 2022-08-09 2022-08-09
US63/396,308 2022-08-09
PCT/US2023/060064 WO2023133389A2 (en) 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies

Publications (2)

Publication Number Publication Date
JP2025501865A true JP2025501865A (ja) 2025-01-24
JP2025501865A5 JP2025501865A5 (enExample) 2026-01-15

Family

ID=87074254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532504A Pending JP2025501865A (ja) 2022-01-05 2023-01-04 抗ｌｉｇｈｔ抗体で喘息を治療する方法

Country Status (6)

Country Link
US (1) US20250002598A1 (enExample)
EP (1) EP4460523A4 (enExample)
JP (1) JP2025501865A (enExample)
AU (1) AU2023205910A1 (enExample)
CA (1) CA3240327A1 (enExample)
WO (1) WO2023133389A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484696B1 (en) * 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
HK1257443A1 (zh) * 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法

Also Published As

Publication number Publication date
EP4460523A2 (en) 2024-11-13
US20250002598A1 (en) 2025-01-02
EP4460523A4 (en) 2025-12-17
AU2023205910A1 (en) 2024-06-06
CA3240327A1 (en) 2023-07-13
WO2023133389A2 (en) 2023-07-13
WO2023133389A3 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
EP2627673B1 (en) Therapies for improving pulmonary function
JP2013544235A5 (enExample)
JP2017507139A (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2006511620A (ja) 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法
US20250002598A1 (en) Methods of Treating Asthma with Anti-LIGHT Antibodies
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
JP2025540348A (ja) 筋炎の処置及び予防のための、抗ｉｌｔ７結合剤
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
HK40114122A (en) Methods of treating asthma with anti-light antibodies
TWI865759B (zh) 涉及過量游離light之方法及治療
AU2021479973A1 (en) Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
US20240158522A1 (en) Methods of Treating Ulcerative Colitis with Anti-LIGHT Antibodies
TW202613164A (zh) 以抗IL-1β抗體治療化膿性汗腺炎之方法
AU2024210360A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251226